필터
“90865” 에 대한 검색 결과 2 건
정렬 기준:
알파벳순 (A-Z)
베스트셀러
huIL33
제품 ID:
C001722
계통(Strain):
C57BL/6NCya
상태:
설명:
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that operates as a crucial "alarmin" molecule within the immune system [1]. Released by epithelial and endothelial cells, as well as other cell types, upon cellular damage or stress, IL-33 signals through its receptor, the IL1RL1/ST2 heterodimer, expressed on various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and innate lymphoid cells type 2 (ILC2s). Receptor engagement activates downstream signaling pathways, notably NF-κB and MAPK, culminating in the production of type 2 cytokines such as IL-4, IL-5, and IL-13, thereby promoting Th2 cell differentiation and orchestrating type 2 immune responses critical for defense against helminths and in allergic inflammation [1-2]. Constitutive expression of IL-33 in barrier tissues positions it as a sentinel, contributing to tissue homeostasis and rapidly responding to environmental insults [3]. Aberrant expression and signaling of IL-33 have been strongly implicated in the pathogenesis of a spectrum of inflammatory conditions, including asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease, highlighting its significance as a potential therapeutic target in these disorders [4].
The huIL33 mouse is a humanized model constructed by replacing the sequence of the mouse Il33 gene in situ with the corresponding sequence from the human IL33 gene. The huIL33 mice can be used for studies on asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, and other inflammatory disorders, as well as for IL33-targeted drug development.
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that operates as a crucial "alarmin" molecule within the immune system [1]. Released by epithelial and endothelial cells, as well as other cell types, upon cellular damage or stress, IL-33 signals through its receptor, the IL1RL1/ST2 heterodimer, expressed on various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and innate lymphoid cells type 2 (ILC2s). Receptor engagement activates downstream signaling pathways, notably NF-κB and MAPK, culminating in the production of type 2 cytokines such as IL-4, IL-5, and IL-13, thereby promoting Th2 cell differentiation and orchestrating type 2 immune responses critical for defense against helminths and in allergic inflammation [1-2]. Constitutive expression of IL-33 in barrier tissues positions it as a sentinel, contributing to tissue homeostasis and rapidly responding to environmental insults [3]. Aberrant expression and signaling of IL-33 have been strongly implicated in the pathogenesis of a spectrum of inflammatory conditions, including asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease, highlighting its significance as a potential therapeutic target in these disorders [4].
The huIL33 mouse is a humanized model constructed by replacing the sequence of the mouse Il33 gene in situ with the corresponding sequence from the human IL33 gene. The huIL33 mice can be used for studies on asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, and other inflammatory disorders, as well as for IL33-targeted drug development.
huIL33/huIL33R
제품 ID:
C002039
계통(Strain):
C57BL/6NCya
상태:
설명:
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an important endogenous alarmin in the immune system [1]. IL-33 is mainly released by barrier tissue cells, such as epithelial cells and endothelial cells, under conditions including mechanical injury, pathogen infection, or oxidative stress. It binds to the IL1RL1/ST2 receptor complex expressed on the surface of various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and group 2 innate lymphoid cells (ILC2s), thereby initiating downstream signaling cascades.
Interleukin-1 receptor-like protein 1 (IL1RL1), also known as ST2 or IL33R, is a member of the interleukin-1 receptor superfamily and serves as the specific receptor for IL-33, playing a critical role in inflammatory responses and immune regulation [2]. The IL1RL1 gene encodes two major protein isoforms: the transmembrane receptor ST2L and the soluble receptor sST2. Functional ST2L is primarily expressed on the surface of various cell types, including immune cells (such as mast cells, helper T cells, and eosinophils), epithelial cells, and endothelial cells [2]. Upon IL-33 stimulation, ST2L activation triggers downstream inflammatory signaling pathways, including NF-κB and MAPK pathways, promoting the release of cytokines and chemokines and participating in various biological processes, including type 2 inflammatory responses, fibrosis, and tumor microenvironment regulation [2-5]. The IL-33/IL1RL1 signaling pathway exhibits complex roles in cancer, potentially promoting tumor cell proliferation, metastasis, and angiogenesis, while also activating antitumor immunity and suppressing tumor growth [3].
The huIL33/huIL33R mouse is a dual-target humanized model obtained by crossing the huIL33 mouse (Catalog No.: C001722) with the huIL1RL1(IL33R) mouse (Catalog No.: C001632). This model is applicable for studying the pathogenesis of inflammatory diseases, including asthma, atopic dermatitis (AD), allergic rhinitis, and inflammatory bowel disease (IBD), as well as tumor-related diseases. It can also be used for the screening, development, and preclinical pharmacodynamic and safety evaluation of therapeutics targeting the IL-33/IL1RL1 pathway.
Items: 1 to 2 of 2
1